243 related articles for article (PubMed ID: 11936752)
1. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
Victor-Vega C; Desai A; Montesinos MC; Cronstein BN
Inflammation; 2002 Feb; 26(1):19-24. PubMed ID: 11936752
[TBL] [Abstract][Full Text] [Related]
2. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors.
Montesinos MC; Desai A; Chen JF; Yee H; Schwarzschild MA; Fink JS; Cronstein BN
Am J Pathol; 2002 Jun; 160(6):2009-18. PubMed ID: 12057906
[TBL] [Abstract][Full Text] [Related]
3. Promotion of Wound Healing by an Agonist of Adenosine A2A Receptor Is Dependent on Tissue Plasminogen Activator.
Montesinos MC; Desai-Merchant A; Cronstein BN
Inflammation; 2015 Dec; 38(6):2036-41. PubMed ID: 25991438
[TBL] [Abstract][Full Text] [Related]
4. Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors.
Montesinos MC; Gadangi P; Longaker M; Sung J; Levine J; Nilsen D; Reibman J; Li M; Jiang CK; Hirschhorn R; Recht PA; Ostad E; Levin RI; Cronstein BN
J Exp Med; 1997 Nov; 186(9):1615-20. PubMed ID: 9348321
[TBL] [Abstract][Full Text] [Related]
5. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
Ladin D
Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ
Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
[TBL] [Abstract][Full Text] [Related]
9. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
Rees RS; Robson MC; Smiell JM; Perry BH
Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
11. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
Landsman A; Agnew P; Parish L; Joseph R; Galiano RD
J Am Podiatr Med Assoc; 2010; 100(3):155-60. PubMed ID: 20479444
[TBL] [Abstract][Full Text] [Related]
12. Adenosine receptors and wound healing.
Cronstein BN
ScientificWorldJournal; 2004 Jan; 4():1-8. PubMed ID: 14755098
[TBL] [Abstract][Full Text] [Related]
13. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
Miller MS
J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
[TBL] [Abstract][Full Text] [Related]
14. A fragment of secreted Hsp90α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice.
Cheng CF; Sahu D; Tsen F; Zhao Z; Fan J; Kim R; Wang X; O'Brien K; Li Y; Kuang Y; Chen M; Woodley DT; Li W
J Clin Invest; 2011 Nov; 121(11):4348-61. PubMed ID: 22019588
[TBL] [Abstract][Full Text] [Related]
15. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
Nagai MK; Embil JM
Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
[TBL] [Abstract][Full Text] [Related]
16. [Becaplermin gel (Regranex gel)].
Senet P
Ann Dermatol Venereol; 2004 Apr; 131(4):351-8. PubMed ID: 15258509
[TBL] [Abstract][Full Text] [Related]
17. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1.
Desai A; Victor-Vega C; Gadangi S; Montesinos MC; Chu CC; Cronstein BN
Mol Pharmacol; 2005 May; 67(5):1406-13. PubMed ID: 15673602
[TBL] [Abstract][Full Text] [Related]
18. Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat.
Fozard JR; Ellis KM; Villela Dantas MF; Tigani B; Mazzoni L
Eur J Pharmacol; 2002 Mar; 438(3):183-8. PubMed ID: 11909610
[TBL] [Abstract][Full Text] [Related]
19. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
Castronuovo JJ; Ghobrial I; Giusti AM; Rudolph S; Smiell JM
Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of platelet-derived growth factor BB in accelerating wound healing in aged versus young animals: the impact of tissue hypoxia.
Wu L; Brucker M; Gruskin E; Roth SI; Mustoe TA
Plast Reconstr Surg; 1997 Mar; 99(3):815-22; discussion 823-4. PubMed ID: 9047202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
